Media Releases

COVID-19 vaccination highly effective in individuals with immune-related inflammatory diseases

Montreal, May 3, 2022 – New findings, published in The Lancet Rheumatology, suggest that people with immune-mediated inflammatory diseases (IMIDs) respond well to vaccination and that the COVID-19 vaccines in Canada are highly effective in protecting them against hospitalization from COVID-19. The results of this study are highly pertinent for people living with rheumatoid arthritis, ankylosing spondylitis (a type of arthritis that characteristically affects the spine), psoriasis (a skin condition), and inflammatory bowel disease (IBD) – the four patient populations included in the study, supported by the Government of Canada, through its COVID-19 Immunity Task Force (CITF).

2022-05-02T17:55:40-04:00May 3, 2022|Media Releases|

Lower vaccination rates among people who use drugs could lead to serious outcomes from COVID-19

Vancouver, April 6, 2022 - As many jurisdictions in Canada begin to ease public health measures intended to limit serious cases and fatalities caused by COVID-19, new research from the BC Centre on Substance Use (BCCSU) and the University of British Columbia (UBC) suggests many people remain at risk of serious disease. The Government [...]

2022-04-05T15:43:05-04:00April 6, 2022|Media Releases|

Government of Canada launches second cycle of national survey to assess the health impacts of the COVID-19 pandemic

Ottawa, Ontario | Public Health Agency of Canada Canada’s response to the COVID-19 pandemic is continually guided by the latest science, evidence and research. To that end, the Government of Canada is actively working with a community of national and international experts to gather evidence on the health impacts of the pandemic, as well [...]

2022-04-01T15:17:33-04:00April 4, 2022|Media Releases|

New study investigates immune response and vaccine hesitancy among First Nations communities

The COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG) are supporting a new study that will work with three First Nations communities to investigate vaccine hesitancy, the immune response to the COVID-19 vaccine and health outcomes after vaccination within those communities. As of November 9, 2021, according to Indigenous Services [...]

2021-12-06T15:32:14-05:00December 7, 2021|Media Releases|

CanPath to study the impact and immune response to COVID-19 infection and vaccination

The Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study is expanding. The Government of Canada is investing $1.9 million through Canada’s COVID-19 Immunity Task Force (CITF) to fund an extension of CanPath’s existing study over a longer period of time, allowing for an additional collection of blood samples and questionnaire responses from participants. [...]

2021-12-01T09:52:04-05:00December 1, 2021|Media Releases|

Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF). Principal investigator Dr. Brian Grunau, Assistant [...]

2021-12-01T09:55:31-05:00December 1, 2021|Healthcare workers, Media Releases|
Go to Top